Interleukin-2 therapy and CD4+ T cells in HIV-1 infection
- 1 January 2006
- journal article
- Published by Elsevier in The Lancet
- Vol. 367 (9505) , 93-95
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patientsJournal of Clinical Investigation, 2005
- In vivo expansion of CD4+CD45RO-CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patientsJournal of Clinical Investigation, 2005
- IL-2–induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferationBlood, 2004
- Changes in thymic function in HIV-positive patients treated with highly active antiretroviral therapy and interleukin-2Clinical and Experimental Immunology, 2001
- Comparison of the Frequency of Interleukin (IL)–2–, Interferon‐γ–, and IL‐4–Producing T Cells in 2 Diseases, Human Immunodeficiency Virus Types 1 and 2, with Distinct Clinical OutcomesThe Journal of Infectious Diseases, 2001
- Pooled Analysis of 3 Randomized, Controlled Trials of Interleukin‐2 Therapy in Adult Human Immunodeficiency Virus Type 1 DiseaseThe Journal of Infectious Diseases, 2000
- Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trialThe Lancet, 1999
- Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patientsAIDS, 1998
- Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency VirusNew England Journal of Medicine, 1996